Company intelligence / Profile preview
Aqualung Therapeutics
Tucson, Arizona, United Statesaqualungtherapeutics.com ↗
- Ownership
- Private
- Employees
- ~30
- Development stage
- Other
01
Overview
The company’s lead program ALT-100 mAb has completed a Phase 1 trial in healthy volunteers and has entered a Phase 2a multi-center clinical trial for moderate/severe ARDS. Preclinical studies have shown efficacy in multiple models of inflammatory and fibrotic diseases. The company’s technology has been validated with significant non-dilutive NIH funding and peer-reviewed publications. No FDA-approved therapies currently exist for ARDS; thus the clinical need remains high.[3][7][8]
- Therapeutic areas
- PulmonologyCardiovascularImmunologyOtherWomen's HealthOncology
- Modalities
- monoclonal antibodies (mAbs)biomarker panelsgenotyping assays[1][3][10]
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
CMAX Clinical Research Group (CRO partner for trials in Australia) [7]
Beyond the preview
Go deeper on Aqualung Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aqualung Therapeutics.